Bessemer Group
TBPH icon

Bessemer Group’s Theravance Biopharma TBPH Stock Holding History

Bessemer Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed – – 2683
2025
Q4 		$0 Hold
1
– – ﹤0.01% 2702
2025
Q3 		$0 Buy
+1
New +$13 ﹤0.01% 2723
2020
Q3 		– Sell
-2,300
Closed -$48K – 1646
2020
Q2 		$48K Buy
+2,300
New +$59.1K ﹤0.01% 1350

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bessemer Group's TBPH Position: Q1 2026 in Review

Bessemer Group sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 1 share.

Bessemer Group first reported a position in TBPH in Q2 2020 and held it in 3 quarters. The position peaked at $48K in Q2 2020. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Bessemer Group reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Bessemer Group sold 1 Theravance Biopharma share in Q1 2026.
  • Bessemer Group first reported a position in Theravance Biopharma in Q2 2020 and held it in 3 quarters.
  • Bessemer Group's Theravance Biopharma position peaked at $48K in Q2 2020.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.